← All organizations
Highest phase reached
Phase 3
First clinical trial
May 24, 2016Last known activity
Dec 1, 2024
Timeline
2000s
- Jan 1, 2004
California Institute for Regenerative Medicine (CIRM)— Founded
Drugs by trial phase (38 distinct, 28 trials)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (12 own, 0 via acquisition)
- allogeneic pancreatic islet cells
- flucytosine
- temozolomide
- human placental derived stem cells
- human retinal progenitor cells
- autologous muscle derived stem cells
- vocimagene amiretrorepvec
- ctns-rd-04
- rp-l201
- autologous bone marrow derived cd34+ hsc cells transduced with the lentiviral vector containing a short-hairpin rna targeting bcl11a
- fetal-derived neural stem cells
- nl-scn2a-002
Indications
Recent trials (29)
- NCT06504381CollaboratorPhase 1/Phase 2Dec 1, 2024
- NCT06504381OfficialPhase 1/Phase 2Dec 1, 2024
- NCT06186401CollaboratorPhase 1Apr 30, 2024
- NCT06314490CollaboratorPhase 1/Phase 2Feb 16, 2024
- NCT06344026CollaboratorPhase 1Jan 23, 2024
- NCT05835895CollaboratorPhase 1Jun 12, 2023
- NCT05353647CollaboratorPhase 2Jul 12, 2022
- NCT05421689CollaboratorPhase 1/Phase 2May 26, 2022
- NCT05306457CollaboratorPhase 1Apr 30, 2022
- NCT05241444CollaboratorPhase 1Mar 22, 2022
- NCT05181540CollaboratorPhase 3Feb 21, 2022
- NCT04652908CollaboratorPhase 1/Phase 2Jun 21, 2021
- NCT04631406CollaboratorPhase 1/Phase 2Jan 4, 2021
- NCT04594031CollaboratorPhase 1Dec 1, 2020
- NCT04604899CollaboratorPhase 2Nov 30, 2020
Details
- Founded
- Oakland, CA, US Jan 1, 2004
- Last known activity
- Dec 1, 2024